A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Trial Profile

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 30 Nov 2017 Results assessing safety and efficacy published in the Blood
    • 22 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 02 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top